[Fetal hemoglobin in children with different neoplasms]

Area of Science:

• Hematology
• Pediatric Oncology
• Molecular Biology

Background:

• Fetal hemoglobin (HbF) levels can be altered in various pediatric malignancies.
• Understanding HbF changes in children with cancer is crucial for assessing disease characteristics and potential therapeutic targets.

Purpose of the Study:

• To investigate the rate of fetal hemoglobin (HbF) in children diagnosed with various malignancies.
• To explore the relationship between HbF levels and different types of cancers in pediatric patients.
• To compare HbF expression patterns in children with cancer to adult counterparts and analyze gamma chain correlations.

Main Methods:

• Studied HbF levels in 123 children across different malignancy groups: acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), and solid tumors (ST).
• Analyzed the gamma G and gamma A chains of HbF in a subset of 14 patients.
• Compared findings with data from adult leukemia and lymphoma patients.

Main Results:

• Children with ALL and AML exhibited the highest HbF rates (2.88% and 2.63%, respectively).
• Hodgkin's disease and NHL groups showed moderate HbF levels (1.89% and 1.81%), while solid tumors had the lowest (1.32%).
• Pediatric cancer patients generally had higher HbF levels than adult leukemia and lymphoma patients. Gamma chain analysis revealed newborn-like patterns in 50% of cases and adult-like patterns in the other 50%.

Conclusions:

• Neoplastic factors in pediatric cancers appear to influence the re-expression of HbF.
• The observed increase in HbF in children with malignancies does not uniformly indicate a reversion to fetal stages, as evidenced by mixed gamma chain correlations.